Cancer is a remarkably complex disease that can affect nearly every system and pathway in the body. A new panel of biomarkers from Myriad RBM (OncologyMAP® 2.0) offers a cast-a-wide net approach to studying cancer’s effects by measuring a number of important targets involved such as angiogenesis, tumor growth, and metastasis. Broad-based panels offer a better chance to discover biomarker patterns – as opposed to focusing on single biomarkers – which can be useful in developing prognostic and companion diagnostic tests.
